{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:53:41Z","timestamp":1791064421013,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Holding SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rbmojournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive BioMedicine Online"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.rbmo.2026.105743","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:39:22Z","timestamp":1781091562000},"page":"105743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human menopausal gonadotrophin in a pre-filled injection pen is non-inferior to the US-approved powder formulation"],"prefix":"10.1016","volume":"53","author":[{"given":"Craig","family":"Witz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Heiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbmo.2026.105743_bib0001","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.fertnstert.2007.08.001","article-title":"A comparison of the efficacy, tolerability, and convenience of two formulations of follitropin-\u03b1 in Iranian woman undergoing intracytoplasmic sperm injection cycles","volume":"90","author":"Aghssa","year":"2008","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2026.105743_bib0002","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/humrep\/del284","article-title":"Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial","volume":"21","author":"Andersen","year":"2006","journal-title":"Human Reproduction"},{"key":"10.1016\/j.rbmo.2026.105743_bib0003","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.clinthera.2013.05.020","article-title":"Insulin Pen Needles: Effects of Extra-Thin Wall Needle Technology on Preference, Confidence, and Other Patient Ratings","volume":"35","author":"Aronson","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.rbmo.2026.105743_bib0004","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1185\/030079907X178784","article-title":"A retrospective comparison of clinical outcomes and satisfaction using reconstituted recombinant gonadotrophins (rFSH) or cartridge rFSH with a pen device in donor oocyte cycles","volume":"23","author":"Christianson","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.rbmo.2026.105743_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1472-6483(10)62033-0","article-title":"Follitropin-\u03b2 administered by pen device has superior local tolerance compared with follitropin-\u03b1 administered by conventional syringe","volume":"3","author":"Craenmehr","year":"2001","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.rbmo.2026.105743_bib0006","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2147\/PPA.S385247","article-title":"Analysis of Nurse and Patient Preferences for Pre-Filled Pen Devices for Self-Injection of Highly Purified Human Menopausal Gonadotrophin (HP-hMG, MENOPUR\u00ae)","volume":"17","author":"De Mesmaeker","year":"2023","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.rbmo.2026.105743_bib0007","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.fertnstert.2011.12.016","article-title":"A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer","volume":"97","author":"Devroey","year":"2012","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2026.105743_bib0008","series-title":"Immunogenicity testing of therapeutic protein products \u2014 developing and validating assays for anti-drug antibody detection","year":"2019"},{"key":"10.1016\/j.rbmo.2026.105743_bib0009","series-title":"Draft guidance for industry: assay development and validation for immunogenicity testing of therapeutic protein products","year":"2016"},{"key":"10.1016\/j.rbmo.2026.105743_bib0010","series-title":"Guidance for industry: Immunogenicity assessment for therapeutic protein products","year":"2014"},{"key":"10.1016\/j.rbmo.2026.105743_bib0011","series-title":"The Plenary Proceedings of the 11th World Congress on in Vitro Fertilisation and Human Reproductive Genetics","first-page":"378","article-title":"In vitro culture of human blastocysts","author":"Garder","year":"1999"},{"key":"10.1016\/j.rbmo.2026.105743_bib0012","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: An update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstet. Gynecol. Surv."},{"key":"10.1016\/j.rbmo.2026.105743_bib0013","doi-asserted-by":"crossref","first-page":"794","DOI":"10.5414\/CP204040","article-title":"First pre-filled pen device with highly purified human menopausal gonadotrophin (HP-hMG, Menopur) in liquid is shown to be bioequivalent to powder for reconstitution","volume":"59","author":"Jonker","year":"2021","journal-title":"Int. Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.rbmo.2026.105743_bib0014","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5653\/cerm.2011.38.1.37","article-title":"Comparison of follitropin \u03b2 administered by a pen device with follitropin \u03b2 administered by a conventional syringe in patients undergoing IVF-ET","volume":"38","author":"Kang","year":"2011","journal-title":"Clin. Exp. Reprod. Med."},{"key":"10.1016\/j.rbmo.2026.105743_bib0015","unstructured":"MENOPUR [package insert], 2018. Parsippany, NJ."},{"key":"10.1016\/j.rbmo.2026.105743_bib0016","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/humrep\/deg234","article-title":"An open, randomized single-centre study to compare the efficacy and convenience of follitropin beta administered by a pen device with follitropin alpha administered by a conventional syringe in women undergoing ovarian stimulation for IVF\/ICSI","volume":"18","author":"Platteau","year":"2003","journal-title":"Human Reproduction"},{"key":"10.1016\/j.rbmo.2026.105743_bib0017","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.fertnstert.2012.05.031","article-title":"Endometriosis and infertility: A committee opinion","volume":"98","year":"2012","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2026.105743_bib0018","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2710.2008.00931.x","article-title":"Comparison of follitropin- administered by a pen device with conventional syringe in an ART programme a retrospective study","volume":"33","author":"Rama Raju","year":"2008","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.rbmo.2026.105743_bib0019","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/17425247.2018.1450386","article-title":"Nurse evaluation of the redesigned fertility pen injector: a questionnaire-based observational survey","volume":"15","author":"Schertz","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.rbmo.2026.105743_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12958-016-0164-y","article-title":"Safety and efficacy of Ovaleap\u00ae (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study","volume":"14","author":"Strowitzki","year":"2016","journal-title":"Reproductive Biology and Endocrinology"},{"key":"10.1016\/j.rbmo.2026.105743_bib0021","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0015-0282(02)03250-8","article-title":"Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization\/intracytoplasmic sperm injection cycles: a randomized, comparative trial","volume":"78","year":"2002","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2026.105743_bib0022","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.fertnstert.2020.03.029","article-title":"Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection","volume":"114","author":"Witz","year":"2020","journal-title":"Fertil. Steril."}],"container-title":["Reproductive BioMedicine Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648326002841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648326002841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:30:16Z","timestamp":1791063016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472648326002841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1472648326002841"],"URL":"https:\/\/doi.org\/10.1016\/j.rbmo.2026.105743","relation":{},"ISSN":["1472-6483"],"issn-type":[{"value":"1472-6483","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human menopausal gonadotrophin in a pre-filled injection pen is non-inferior to the US-approved powder formulation","name":"articletitle","label":"Article Title"},{"value":"Reproductive BioMedicine Online","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbmo.2026.105743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105743"}}